INS and type 2 diabetes mellitus: The safety of lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and sulfonylurea, when combined with basal insulin therapy, was examined in the LixiRam trial on people with type 2 diabetes who prefer to fast throughout Ramadan [38].